Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
Information source: M.D. Anderson Cancer Center
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glioblastoma Multiforme; Anaplastic Glioma
Intervention: Vorinostat (Drug); Isotretinoin (Drug); Surgical Resection (Procedure); Temozolomide (Drug)
Phase: Phase 1/Phase 2
Sponsored by: M.D. Anderson Cancer Center
Official(s) and/or principal investigator(s):
Vinay K. Puduvalli, MD, Principal Investigator, Affiliation: M.D. Anderson Cancer Center
Vinay K. Puduvalli, MD, Phone: 713-792-2883
1. To determine the maximum tolerated dose (MTD) of vorinostat/isotretinoin (cRA),
temozolomide (TMZ)/cRA and vorinostat/cRA/TMZ combinations in adult patients with recurrent
glioblastoma multiforme (GBM) and anaplastic gliomas.
1. To determine the efficacy of vorinostat/cRA versus TMZ/cRA versus vorinostat/cRA/TMZ in
patients with recurrent GBM as determined by Progression Free Survival (PFS) using an
adaptive randomization phase II trial design.
2. To determine the radiological response, progression free survival at 6 months, overall
survival and unexpected toxicity in the three treatment arms.
3. To obtain exploratory data regarding histone 3 and 4 acetylation and p21 levels in
tumor tissue and peripheral monocytes in a subset of surgical patients and in
non-surgical patients with available tissue from previous surgical procedures.
4. To evaluate the occurrence of symptoms and correlate to disease progression and
tolerance to treatment using the MD Anderson Symptom Inventory-Brain Tumor Module
(MDASI-BT) self-reporting tool.
Official title: Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Maximum tolerated dose (MTD)
Temozolomide is designed to kill cancer cells by damaging DNA (the genetic material of
cells). The damaged DNA may cause tumor cell death. Isotretinoin is designed to decrease
the growth rate of gliomas and may decrease the blood supply to the tumor. Vorinostat is
designed to change the levels of production of several proteins in the tumor cells and
either kill or stop their growth. Researchers hope that it may improve the effects of
isotretinoin and temozolomide on malignant gliomas.
There are 2 phases to this study. In Phase 1, researchers are trying to find the highest
tolerable dose of the study drugs that can be given together in each of the 3 study groups.
Up to the first 54 participants enrolled in this study will be enrolled in Phase 1. If you
have an anaplastic glioma you are only allowed to participate in the Phase I part of this
study. In Phase 2, researchers will be trying to find out which of the 3 groups is best for
the treatment of gliomas.
If you are found to be eligible to take part in this study and you are enrolled in Phase 1,
you may be assigned to either Group 1 or Group 2. Group 1 will receive vorinostat and
isotretinoin. Group 2 will receive temozolomide and isotretinoin. If you enter the study
after the highest tolerable doses for Groups 1 and 2 are found, you will be assigned to
Group 3 and will receive vorinostat, isotretinoin, and temozolomide. No matter which group
you are assigned to, every 28 days will be called a study "cycle. During Days 21-28, you
will not receive any study drugs. This is called the "rest" period.
The first 3 participants in each study group will receive the lowest dose levels of the
study drugs. If there are no intolerable side effects seen at that dose level after 4 weeks
(or, 1 study "cycle"), the next 3 participants enrolled to each study group will receive a
higher dose of the study drugs. If there are no intolerable side effects at that second
dose level, 3 more participants will be enrolled in each study group at the next (higher)
dose level. In any study group, if 1 participant has intolerable side effects, another 3
participants will be enrolled at the same dose level. If a second participant at that dose
level has intolerable side effects, another group of 3 participants will then be enrolled in
that study group at the earlier (lower) dose level, to make sure that it is the highest safe
dose combination that can be given.
Once the phase I portion of the study is completed, the Phase II portion will begin. If you
are found to be eligible to take part in this study and are 1 of the first 30 participants
in Phase II, you will be randomly assigned (as in the roll of dice) to 1 of the same 3
groups as participants in the Phase I portion of the study.
If you are found to be eligible to take part in this study and you are not one of the first
30 participants assigned to Phase II, you will be assigned to a study group based on how
well each group is performing. If each group is about as effective as the other groups, you
may still have an equal chance of being assigned to each group. If 1 or 2 groups appear to
be more effective, you will have a higher chance of being assigned to the more effective
If you are eligible to participate in the Phase II portion of the study but your doctor has
recommended that you have surgery to remove a tumor that has come back, you would have the
surgery before being assigned to a study group. This part of the study is done to learn the
effects of vorinostat on tumor tissue and blood cells. Up to 10 participants will take part
in this portion of the study.
If you participate in this part of the study, you will be given vorinostat by mouth once
daily for 3 days in a row before your surgery. The last dose of the drug will be given the
morning of surgery. After the surgery, a portion of the remaining tumor tissue will be used
to measure the drug levels and the effects of vorinostat on the tumor. Blood (about 1
teaspoon) will be drawn before and after the first dose of vorinostat, and at the same time
as the tissue removal during surgery. This blood will be used to study the drug levels and
the effects of the drug in normal blood cells and to match these findings with that in the
After you have recovered from the effects of surgery (about 2 weeks), you will then be
randomly assigned or assigned based on known effectiveness as all other members of the Phase
All participants, regardless of being assigned to Phase 1 or 2, will receive the same study
drugs (based on the group they are assigned to) and the same procedures and testing.
If you are assigned to Group 1, you will take vorinostat by mouth once a day during Days
1-14. You will also take isotretinoin by mouth 2 times a day on Days 1-21.
If you are assigned to Group 2, you will take isotretinoin by mouth 2 times a day on Days
1-21. You will take temozolomide by mouth once a day on Days 1-7 and Days 15-21.
If you are assigned to Group 3, you will take vorinostat by mouth once a day during Days 1-7
and Days 15-21. You will also take isotretinoin by mouth 2 times a day on Days 1-21. You
will also take temozolomide by mouth once a day on Days 1-7 and Days 15-21.
About every week during Cycle 1 and about every 2 weeks after that, blood (less than 1
tablespoon) will be drawn for routine tests. Blood (about 2 tablespoons) will also be drawn
about every 2 weeks during Cycle 1 and then at the end of every cycle to check your liver
and kidney function and to see how well you blood clots.
At the end of Cycle 1 and the at the end of every odd numbered cycle (Cycles 3, 5, 7 and so
on), blood (about 1 teaspoon) will be drawn for lipid testing (a check of different types of
fat in the blood, such as cholesterol).
Women who are able to have children must have a negative blood (about 1 teaspoon) pregnancy
test before each new cycle. If at any point during the study your treatment is delayed, you
will also have a pregnancy test before restarting therapy.
You will have a complete physical and neurological exam at the end of Cycle 1 and 2, then
at the end of every other cycle (Cycles 4, 6, 8 and so on). These tests may be performed
more often if your doctor thinks it is necessary. Your performance status will be recorded.
You will have a complete medical history and physical exam, including measurement of your
weight. You will have a neurological exam.
You will have an MRI scan at the end of every other cycle (Cycles 2, 4, 6, 8 and so on).
These tests may be performed more often if your doctor thinks it is needed.
You will receive the treatment for up to 1 year, after which you will continue to be
monitored on the study provided your disease does not get worse. You may continue to receive
treatment beyond 1 year and remain on study if your doctor decides that it is in your best
Once you are no longer receiving the study drugs, you will have an end-of-study visit. At
this visit, you will have another complete physical exam. Blood (less than 2 tablespoons)
will be drawn for routine tests, to check your liver and kidney function, to check your
bloods ability to clot, and for lipid testing. You will have an MRI.
After you have your end-of-study visit, you will have a follow-up evaluation (a clinic visit
or telephone call) about every 3 months to find out how you are feeling. These visits/calls
will continue indefinitely. The phone calls will take about 15 minutes.
This is an investigational study. Isotretinoin, temozolomide, and vorinostat are FDA
approved drugs and commercially available. The use of these drugs in this combination is
investigational. Up to 189 patients will take part in this study. All will be enrolled at
M. D. Anderson.
Minimum age: 18 Years.
Maximum age: N/A.
1. Patients with histologically proven supratentorial glioblastoma multiforme,
gliosarcoma or anaplastic glioma will be eligible for the Phase I component of this
protocol. Anaplastic gliomas include anaplastic astrocytoma, anaplastic
oligodendroglioma, anaplastic mixed oligoastrocytoma, or malignant glioma NOS.
Patients will be eligible if the original histology was low-grade glioma and a
subsequent histological diagnosis of a malignant glioma is made. Only patients with
histologically proven supratentorial glioblastoma multiforme or gliosarcoma will be
eligible for the Phase II component.
2. Patients must have shown unequivocal evidence for tumor recurrence or progression by
MRI scan and should have failed radiation therapy. The scan done prior to study entry
documenting progression will be reviewed by the treating physician to document
changes in tumor dimension to confirm recurrence. Patients with prior therapy that
included interstitial brachytherapy or stereotactic radiosurgery must have
confirmation of true progressive disease rather than radiation necrosis.
3. Patients may have had up to 2 prior relapses provided the functional status and other
eligibility criteria for enrollment are met.
4. All patients must sign an informed consent indicating that they are aware of the
investigational nature of this study in keeping with the policies of this hospital.
5. The baseline on-study MRI should be performed within 14 days (+ 3 working days) prior
to registration and on a steroid dosage that has been stable or decreasing for at
least 5 days. If the steroid dose is increased between the date of imaging and the
initiation of therapy (or at that time), a new baseline MRI is required. The same
type of scan, i. e., MRI, must be used throughout the period of protocol treatment for
6. Patients having undergone recent resection of recurrent or progressive tumor will be
eligible as long as they have recovered from the effects of surgery. Evaluable or
measurable disease following resection of recurrent tumor is not mandated for
eligibility into the study. To best assess the extent of residual measurable disease
post-operatively, a MRI should be done no later than 96 hours in the immediate
post-operative period or 4-6 weeks post-operatively.
7. Patients must be 18 years old or older.
8. Patients must have a Karnofsky performance status equal or greater than 60.
9. Patients must have recovered from the toxic effects of prior therapy to < grade 2 non
hematological or grade 2 or lesser hematological toxicity per CTC ver 3 (except deep
vein thrombosis): 4 weeks from prior cytotoxic therapy and/or at least two weeks from
vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, and
1 week for non-cytotoxic agents, e. g., interferon, tamoxifen, cis-retinoic acid, etc.
(radiosensitizer does not count). Patients who receive anticancer agents for
non-therapeutic purposes unrelated to this study
10. ( 9. continued) (such as presurgically for obtaining pharmacology data for the agent)
will be eligible to enter the study provided they have recovered from the toxic
effects of the agent if any. Because the trial is based on the hypothesis that the
combination of agents used will be synergistic in their effects, and that HDAC
inhibition will potentially overcome resistance to retinoids, prior treatment with
cRA is allowed. Any questions related to the definition of non-cytotoxic agents
should be directed to the Study Chair.
11. Patients must have adequate bone marrow function (ANC = or > 1,500/mm^3 and platelet
count of = or > 100,000/mm^3), adequate liver function (SGPT = or < 3 times normal
and alkaline phosphatase = or < 2 times normal, bilirubin = or <1. 5 mg/dl), adequate
renal function (BUN and creatinine = or <1. 5 times institutional normal) and normal
serum amylase and lipase prior to starting therapy. Elevated cholesterol and
triglycerides are not a contraindication to study enrollment, but should be managed
as clinically appropriate.
12. Patients must be willing and able to comply with the FDA mandated iPLEDGE program for
treatment with isotretinoin (cRA). Patients must sign specific informed consents for
treatment with cRA, as mandated by iPLEDGE guidelines. Women of childbearing
potential must not be pregnant, must not be breast-feeding and must practice adequate
contraception during and one month after participation in the study. Male patients on
treatment with vorinostat must agree to use an adequate method of contraception for
the duration of the study, and for 30 days after the last dose of study medication.
13. Prior treatment with dose dense regimens of temozolomide is not allowed (e. g, 7 days
on/7 days off, 21 day/28 day and daily low dose continuous dosing). However, standard
day 1-5 dosing and low dose daily dosing as part of chemoradiation therapy are
1. Patients with a history of any other cancer (except non-melanoma skin cancer or
carcinoma in-situ of the cervix or bladder), unless in complete remission and off of
all therapy for that disease for a minimum of 3 years.
2. Patients must not have: a) active infection; b) disease that will obscure toxicity or
dangerously alter drug metabolism, especially liver disease; c) serious intercurrent
medical illness; d) prior recurrence with other HDAC inhibitors. However, patients
who have received anticancer agents for non-therapeutic purposes (for eg., as part of
a pharmacology study without therapeutic intent) will remain eligible.
3. Pregnant and breast feeding women.
4. Patients receiving valproic acid (VPA), an anticonvulsant drug with HDAC inhibitor
properties, will be excluded, unless they are switched to an alternative agent prior
to treatment initiation. No wash out period is required.
5. Patients on previous treatment with carboplatin.
6. Patients with a known allergy to any component of vorinostat, or a known allergy to
temozolomide and/or isotretinoin.
7. Patient must be able to tolerate the procedures required in this study including
periodic blood sampling, study related assessments, and management at the treating
institution for the duration of the study. Inability to comply with protocol or study
procedures (for example, an inability to swallow tablets) will be an exclusion
Locations and Contacts
Vinay K. Puduvalli, MD, Phone: 713-792-2883
UT MD Anderson Cancer Center, Houston, Texas 77030, United States; Recruiting
Vinay K. Puduvalli, MD, Principal Investigator
The University of Texas M.D.Anderson Cancer Center
Starting date: November 2007
Last updated: September 12, 2011